Edition:
United Kingdom

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

34.92USD
16 Nov 2018
Change (% chg)

$-0.22 (-0.63%)
Prev Close
$35.14
Open
$34.94
Day's High
$35.45
Day's Low
$34.72
Volume
1,453,164
Avg. Vol
1,599,423
52-wk High
$47.81
52-wk Low
$30.34

Select another date:

Fri, Nov 9 2018

Mylan and Theravance's COPD treatment gets FDA approval

Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

UPDATE 2-Mylan and Theravance's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Mylan and Theravance Biopharma's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Drugmaker Mylan's profit beats; puts no timeline on strategic options

Mylan NV beat analysts' estimates for third-quarter profit on Monday, as the generic drugmaker reported higher sales of its products in emerging markets and said it had not set any timeline on evaluating its strategic alternatives.

UPDATE 3-Drugmaker Mylan's profit beats; puts no timeline on strategic options

Nov 5 Mylan NV beat analysts' estimates for third-quarter profit on Monday, as the generic drugmaker reported higher sales of its products in emerging markets and said it had not set any timeline on evaluating its strategic alternatives.

Mylan's quarterly revenue falls 4 pct

Nov 5 Drugmaker Mylan NV reported a 4 percent fall in third-quarter revenue on Monday, hit by low prices of generic drugs in the United States and a continuing global shortage of its emergency allergy injection EpiPen.

Mylan, Fujifilm win EU okay for copy of AbbVie's Humira

LONDON, Sept 20 Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won European approval to market a cheaper copy of AbbVie's $18-billion-a-year biologic drug Humira, the world's best-selling prescription medicine.

BRIEF-Mylan Closes Deal With Novartis To Commercialize Certain Global Cystic Fibrosis Products

* MYLAN - CLOSED DEAL WITH NOVARTIS TO BUY WORLDWIDE RIGHTS TO COMMERCIALIZE GLOBAL CYSTIC FIBROSIS PRODUCTS CONSISTING OF TOBI PODHALER & TOBI SOLUTION Source text for Eikon: (https://bit.ly/2oJcNd7) Further company coverage:

FDA extends EpiPen expiry date to combat shortage

The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.

U.S. FDA extends EpiPen expiry date to combat shortage

Aug 21 The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.

Select another date: